Skip to main content

Advertisement

SpringerLink
Log in

Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Cost-effective intervention thresholds (ITs) based on FRAX® were determined for Portugal. Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8.8 and 2.5 %, respectively. The aim of the present study was to identify the 10-year probabilities of a major and hip osteoporotic fracture using FRAX® validated for Portugal, above which pharmacologic interventions become cost effective in the Portuguese context. A previously developed and validated state transition Markov cohort model was populated with epidemiologic, economic and quality-of-life fracture data from Portugal. Cost-effectiveness of FRAX®-based ITs was calculated for generic alendronate and proprietary zoledronic acid, denosumab and teriparatide were compared to “no intervention”, assuming a WTP of €32,000 (two times national Gross Domestic Product per capita) per QALYs. In the Portuguese epidemiological and economic context, treatment with generic alendronate was cost effective for men and women aged 50 years or more, with 10-year probabilities at or above 8.8 % for major osteoporotic fractures and 2.5 % for hip fractures. Cost-effective threshold 10-year probabilities for major osteoporotic and hip fractures were higher for zoledronic acid (20.4 and 10.1 %), denosumab (34.9 and 10.1 %) and teriparatide (77.8 and 62.6 %), respectively. A tool is provided to perform the calculation of cost-effective ITs for different medications, according to age group and diverse levels of WTP. Cost-effective ITs, for different medications, age groups and WTP, based on 10-year probabilities of major and hip fracture probabilities calculated with FRAX are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. Document can be downloaded at https://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=5&ved=0CDkQFjAE&url=https%3A%2F%2Fwww.ine.pt%2Fngt_server%2Fattachfileu.jsp%3Flook_parentBoui%3D217825026%26att_display%3Dn%26att_download%3Dy&ei=rRxwVaWVA4T8UoT-gsAL&usg=AFQjCNF425t1t09yNBr9DzzHU9gL_q5DXQ. Accessed 4 June 2015.

References

  1. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239–2256. doi:10.1007/s00198-012-1964-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(1–2):136. doi:10.1007/s11657-013-0136-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton Iii LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, Van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046

    Article  CAS  PubMed  Google Scholar 

  4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397. doi:10.1007/s00198-007-0543-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411. doi:10.1007/s00198-011-1713-z

    Article  CAS  PubMed  Google Scholar 

  6. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57. doi:10.1007/s00198-012-2074-y

    Article  CAS  PubMed  Google Scholar 

  7. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408. doi:10.1007/s00198-008-0712-1

    Article  CAS  PubMed  Google Scholar 

  8. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447. doi:10.1007/s00198-007-0550-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lippuner K, Johansson H, Borgstrom F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX(R) in Switzerland. Osteoporos Int 23(11):2579–2589. doi:10.1007/s00198-011-1869-6

    Article  CAS  PubMed  Google Scholar 

  10. Makras P, Athanasakis K, Boubouchairopoulou N, Rizou S, Anastasilakis AD, Kyriopoulos J, Lyritis GP (2015) Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int 26(7):1949–1957. doi:10.1007/s00198-015-3055-8

    Article  CAS  PubMed  Google Scholar 

  11. Marques A, Mota A, Canhao H, Romeu JC, Machado P, Ruano A, Barbosa AP, Dias AA, Silva D, Araujo D, Simoes E, Aguas F, Rosendo I, Silva I, Crespo J, Alves JD, Costa L, Mascarenhas M, Lourenco O, Ferreira PL, Lucas R, Roque R, Branco JC, Tavares V, Johansson H, Kanis J, Pereira da Silva JA (2013) A FRAX model for the estimation of osteoporotic fracture probability in Portugal. Acta Reumatol Port 38(2):104–112

    PubMed  Google Scholar 

  12. Ferreira LN, Ferreira PL, Pereira LN, Oppe M (2013) EQ-5D Portuguese population norms. Qual Life Res 23(2):425–430. doi:10.1007/s11136-013-0488-4

    Article  PubMed  Google Scholar 

  13. Marques A, Lourenco O, da Silva JA (2015) The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. Osteoporos Int. doi:10.1007/s00198-015-3171-5

    Google Scholar 

  14. Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22(3):955–965. doi:10.1007/s00198-010-1291-5

    Article  CAS  PubMed  Google Scholar 

  15. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982. doi:10.1007/s00198-010-1424-x

    Article  CAS  PubMed  Google Scholar 

  16. Strom O, Jonsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 24(4):1491–1502. doi:10.1007/s00198-012-2115-6

    Article  CAS  PubMed  Google Scholar 

  17. Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews (NICE). The University of Sheffield, School of Health and Related Research. http://www.nice.org.uk/guidance/index.jsp?action=download&o=36718. Accessed 5 Jan 2015

  18. de Pina MF, Alves SM, Barbosa M, Barros H (2008) Hip fractures cluster in space: an epidemiological analysis in Portugal. Osteoporos Int 19(12):1797–1804. doi:10.1007/s00198-008-0623-1

    Article  PubMed  Google Scholar 

  19. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669–674

    Article  CAS  PubMed  Google Scholar 

  20. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(3):495–505. doi:10.1007/s00198-009-0989-8

    Article  CAS  PubMed  Google Scholar 

  21. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599–603. doi:10.1007/s001980050105

    Article  CAS  PubMed  Google Scholar 

  22. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteopor Int 15(1):38–42. doi:10.1007/s00198-003-1490-4

    Article  CAS  Google Scholar 

  23. Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA (2014) Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int 25(1):325–337. doi:10.1007/s00198-013-2521-4

    Article  CAS  PubMed  Google Scholar 

  24. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. doi:10.1056/nejm200105103441904

    Article  CAS  PubMed  Google Scholar 

  25. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4–15. doi:10.1016/j.bone.2007.10.019

    Article  CAS  PubMed  Google Scholar 

  26. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL (2012) Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326. doi:10.1007/s00198-011-1780-1

    Article  CAS  PubMed  Google Scholar 

  27. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312

    Article  CAS  PubMed  Google Scholar 

  28. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493

    Article  CAS  PubMed  Google Scholar 

  29. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17(10):1459–1471. doi:10.1007/s00198-006-0107-0

    Article  CAS  PubMed  Google Scholar 

  30. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26. doi:10.1007/s00198-003-1463-7

    Article  CAS  PubMed  Google Scholar 

  31. Royston P, Altman DG (1997) Approximating statistical functions by using fractional polynomial regression. J Roy Stat Soc 46(3):411–422

    Google Scholar 

  32. Sauerbrei W, Meier-Hirmer C, Benner A, Royston P (2006) Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 50(12):3464–3485

    Article  Google Scholar 

  33. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold. Pharmacoeconomics 26(9):733–744

    Article  PubMed  Google Scholar 

  34. Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. Technical Report, p61, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield

  35. European Commission Economic and Financial Affairs. http://ec.europa.eu/economy_finance/ameco/user/serie/ResultSerie.cfm. Accessed 7 Feb 2015

  36. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19(14):1–503v–vi. doi:10.3310/hta19140

    Article  PubMed  PubMed Central  Google Scholar 

  37. Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155(11):751–761. doi:10.7326/0003-4819-155-11-201112060-00007

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nshimyumukiza L, Durand A, Gagnon M, Douville X, Morin S, Lindsay C, Duplantie J, Gagne C, Jean S, Giguere Y, Dodin S, Rousseau F, Reinharz D (2013) An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 28(2):383–394. doi:10.1002/jbmr.1758

    Article  PubMed  PubMed Central  Google Scholar 

  39. Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25(1):51–60. doi:10.1007/s00198-013-2551-y

    Article  CAS  PubMed  Google Scholar 

  40. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16(6):581–589. doi:10.1007/s00198-004-1780-5

    Article  PubMed  Google Scholar 

  41. Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Tremollieres F, Roux C (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(3):304–313. doi:10.1016/j.jbspin.2012.02.014

    Article  PubMed  Google Scholar 

  42. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381. doi:10.1007/s00198-014-2794-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Colombo GL, Montecucco CM (2013) Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clin Cases Miner Bone Metab 10(3):195–198

    PubMed  Google Scholar 

  44. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30(2):213–221. doi:10.1007/s00296-009-0940-5

    Article  CAS  PubMed  Google Scholar 

  45. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202–210

    Article  CAS  Google Scholar 

  46. Siggeirsdottir K, Aspelund T, Johansson H, Gudmundsson EF, Mogensen B, Jonsson BY, Gudnason V, McCloskey E, Oden A, Sigurdsson G, Kanis JA (2014) The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporos Int 25(10):2445–2451. doi:10.1007/s00198-014-2777-3

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study is supported by unrestricted grants from the Direção Geral da Saúde and Amgen, which had no role in the design of the study, the writing or review of the paper.

Author information

Authors and Affiliations

  1. Rheumatology Department, Centro Hospitalar Universitário de Coimbra, 3000-075, Coimbra, Portugal

    Andréa Marques & José António P. da Silva

  2. Health Sciences Research Unit: Nursing (UICiSA:E), Coimbra, Portugal

    Andréa Marques

  3. Faculty of Economics, Centro de Estudos e Investigação em Saúde da Universidade de Coimbra, University of Coimbra, Coimbra, Portugal

    Óscar Lourenço

  4. Quantify Research, Hantverkargatan 8, 112 21, Stockholm, Sweden

    Gustaf Ortsäter & Fredrik Borgström

  5. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

    John A. Kanis

  6. Faculty of Medicine, University of Coimbra, Coimbra, Portugal

    José António P. da Silva

Authors
  1. Andréa Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Óscar Lourenço
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gustaf Ortsäter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fredrik Borgström
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José António P. da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andréa Marques.

Ethics declarations

Conflicts of interest

Andréa Marques, Óscar Lourenço, Gustaf Ortsäter, Fredrik Borgström, John A. Kanis and José António Pereira da Silva declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 114 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marques, A., Lourenço, Ó., Ortsäter, G. et al. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. Calcif Tissue Int 99, 131–141 (2016). https://doi.org/10.1007/s00223-016-0132-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-016-0132-8

Keywords

Search

Navigation